Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.45 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306815 | 0.86 | CSNK2A2 (0.44) | TRPV1CSNK2A2CSNK2A1ADORA2BPTGS2 | |
| SCHEMBL5133267 | 0.86 | TRPV1 (0.55) | TRPV1PRPS1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL308437 | 0.85 | CSNK2A2 (0.43) | TRPV1CSNK2A2CSNK2A1ADORA2BPTGS2 | |
| Hydrochloric Acid SCHEMBL308173 | 0.85 | CSNK2A2 (0.43) | TRPV1CSNK2A2CSNK2A1ADORA2BPTGS2 | |
| SCHEMBL308328 | 0.81 | PTGS2 (0.48) | TRPV1CSNK2A2CSNK2A1ADORA2BPTGS2 | |
| SCHEMBL308444 | 0.78 | PRPS1 (0.51) | TRPV1CSNK2A2CSNK2A1PRPS1ADORA2B | |
| SCHEMBL3038500 | 0.75 | CSNK2A2 (0.53) | CSNK2A2CSNK2A1PRPS1ADORA2BPTGS2 | |
| SCHEMBL2693569 | 0.74 | TRPV1 (0.67) | TRPV1PRPS1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL9988203 | 0.74 | TRPV1 (0.71) | TRPV1SMN1; SMN2LMNAALDH1A1TDP1 | |
| SCHEMBL9988201 | 0.74 | TRPV1 (0.62) | TRPV1PRPS1SMN1; SMN2CYP2C9IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051967-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | NEOMED INST (CA) | 2014-12-31 | — | — | EP | disclosed |
| EP-2051967-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | NEOMED INST (CA) | 2014-12-31 | — | — | EP | disclosed |
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| EP-1966156-B1 | NEW COMPOUNDS III | ASTRAZENECA AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| EP-1966156-B1 | NEW COMPOUNDS III | ASTRAZENECA AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| US-20080221188-A1 | New Benzimidazole Derivatives | ASTRAZENECA R&D SODERTALJE (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20080221188-A1 | New Benzimidazole Derivatives | ASTRAZENECA R&D SODERTALJE (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1966156-A2 | NEW COMPOUNDS III | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| US-20080171770-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171770-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171770-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008018827-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008018827-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007073303-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR 1 (VRL) INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007073303-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES AS VANILLOID RECEPTOR 1 (VRL) INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221188-A1 | New Benzimidazole Derivatives | OPRD1, OPRK1, SDHA | TRPV1 10/4885CSNK2A2 496/4885CSNK2A1 559/4885 |
| US-20080171770-A1 | Compounds | REN, PCSK9, SLC10A1 | TRPV1 91/4885CSNK2A2 1416/4885CSNK2A1 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.